前列腺癌胚系变异患病率及对现有基因检测指南的启示
这项横断面研究分析了2013至2018年间接受胚系基因检测的3607例前列腺癌患者,其中620例(17.2%)检出阳性胚系变异,仅30.7%位于BRCA1/2基因;按NCCN遗传/家族性乳腺和卵巢指南,229例(37%)阳性变异者本不符合检测标准。作者认为现有NCCN指南和Gleason评分无法可靠分层患者,需重新审视当前指南。
要点
- 3607例前列腺癌患者中620例(17.2%)检出阳性胚系变异,仅30.7%为BRCA1/2变异。
- HOXB13阳性变异见于30例(4.5%),DNA错配修复变异占总检测人群变异的1.74%。
- 按NCCN遗传/家族性乳腺和卵巢指南,229例(37%)阳性变异者本不会被批准进行基因检测。
核心结论
- 现有NCCN指南和Gleason评分无法可靠区分前列腺癌患者是否存在致病性胚系变异。
- 本研究检出的大多数阳性基因检测结果对患者及其家族有重要管理意义,凸显重新审视当前指南的必要性。
研究设计与样本
- 横断面研究,纳入2013至2018年间接受胚系基因检测的3607例有前列腺癌个人史的男性,未按家族史、疾病分期或诊断年龄筛选。
- 转诊检测在通过临床实验室改进修正案/美国病理学家学会认证的诊断实验室完成。
- 全部分析于2017年2月至2018年8月间进行。
主要发现
- 3607例患者中620例(17.2%)检出阳性胚系变异,其中仅30.7%为BRCA1/2变异。
- HOXB13阳性变异见于30例患者(4.5%),该基因仅与前列腺癌风险相关。
- DNA错配修复变异占总检测人群变异的1.74%,具有重要已知治疗意义。
- 自报家族史分析显示,229例(37%)阳性变异者按NCCN遗传/家族性乳腺和卵巢指南本不会被批准进行基因检测。
关键数值与推荐
- 检测时平均(SD)年龄67(9.51)岁,诊断时平均年龄60(9.05)岁。
- 阳性胚系变异定义为致病性、可能致病性及风险增加变异。
- 按NCCN遗传/家族性乳腺和卵巢指南评估患者是否符合基因检测标准。
临床怎么用
- 作者认为当前NCCN指南和Gleason评分无法可靠分层前列腺癌患者是否存在致病性胚系变异。
- 作者指出本研究检出的大多数阳性结果对患者及家族有重要管理意义,并强调需重新审视当前指南。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prostate cancer is the third leading cause of cancer-related death in men in the United States. Although serious, most of these diagnoses are not terminal. Inherited risk for prostate cancer is associated with aggressive disease and poorer outcomes, indicating a critical need for increased genetic screening to identify disease-causing variants that can pinpoint individuals at increased risk for metastatic castration-resistant prostate cancer. OBJECTIVE: To identify positive (pathogenic, likely pathogenic, and increased risk) germline variants in a large prostate cancer cohort and to evaluate the usefulness of current practice guidelines in recognizing individuals at increased risk for prostate cancer who would benefit from diagnostic genetic testing. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of data from 3607 men with a personal history of prostate cancer who underwent germline genetic testing between 2013 and 2018 and were unselected for family history, stage of disease, or age at diagnosis. Referral-based testing was performed at a Clinical Laboratory Improvement Amendments/College of American Pathologists-certified diagnostic laboratory. All analysis took place between February 2017 and August 2018. MAIN OUTCOMES AND MEASURES: The frequency and distribution of positive germline variants, and the percentage of individuals with prostate cancer who met National Comprehensive Cancer Network (NCCN) guidelines for germline genetic testing. RESULTS: Of 3607 men (mean [SD] age at testing, 67 [9.51] years; mean age at diagnosis, 60 [9.05] years) with a personal diagnosis of prostate cancer who were referred for genetic testing, 620 (17.2%) had positive germline variants, of which only 30.7% were variants in BRCA1/2. Positive variants in HOXB13, a gene associated only with prostate cancer risk, were identified in 30 patients (4.5%). DNA mismatch repair variants with substantial known therapeutic implications were detected in 1.74% of variants in the total population tested. Examination of self-reported family histories indicated that 229 individuals (37%) with positive variants in this cohort would not have been approved for genetic testing using the NCCN genetic/familial breast and ovarian guidelines for patients with prostate cancer. CONCLUSIONS AND RELEVANCE: Current NCCN guidelines and Gleason scores cannot reliably stratify patients with prostate cancer for the presence or absence of pathogenic germline variants. Most positive genetic test results identified in this study have important management implications for patients and their families, which underscores the need to revisit current guidelines.
引用
- Nicolosi P, Ledet E, Yang S, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019. PMID: 30730552. doi:10.1001/jamaoncol.2018.6760
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。